MARKET

CLBS

CLBS

Caladrius Biosci
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4601
+0.0001
+0.02%
After Hours: 0.4501 -0.01 -2.17% 18:31 05/24 EDT
OPEN
0.4600
PREV CLOSE
0.4600
HIGH
0.4680
LOW
0.4600
VOLUME
257.34K
TURNOVER
0
52 WEEK HIGH
1.680
52 WEEK LOW
0.4019
MARKET CAP
27.84M
P/E (TTM)
-1.1648
1D
5D
1M
3M
1Y
5Y
Caladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease Study
Benzinga · 12h ago
Caladrius suspends enrollment in mid-stage study for heart disease candidate
Caladrius Biosciences (NASDAQ:CLBS) has suspended enrollment in a phase 2 trial of Xowna for coronary microvascular dysfunction and will conduct an interim analysis. Shares are up 4% in after-hours trading. The company
Seekingalpha · 1d ago
BRIEF-Caladrius Biosciences Provides Update On Phase 2B Freedom Trial Of Xowna® In Coronary Microvascular Dysfunction
reuters.com · 1d ago
Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial Next development steps for XOWNA® to be announced by year-end 2022 following regulatory and business review Caladrius Manage...
GlobeNewswire · 1d ago
BRIEF-Caladrius Biosciences Announces Idmc Recommendation To Advance Clbs201 Trial For Treatment Of Diabetic Kidney Disease
reuters.com · 5d ago
Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease
Independent Data Monitoring Committee advises continuation of trial without modification No safety or tolerability concerns observed in the first two patients dosed Top-line data from all subjects expected by the first quarter of 2023 BASKING RIDGE, N.J., ...
GlobeNewswire · 5d ago
Caladrius Biosciences to Proceed With Patient Enrollment for CLBS201 Phase 1b Study
MT Newswires · 5d ago
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse di...
GlobeNewswire · 6d ago
More
No Data
Learn about the latest financial forecast of CLBS. Analyze the recent business situations of Caladrius Biosci through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CLBS stock price target is 8.00 with a high estimate of 10.00 and a low estimate of 6.00.
High10.00
Average8.00
Low6.00
Current 0.4601
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 42
Institutional Holdings: 8.78M
% Owned: 14.51%
Shares Outstanding: 60.52M
TypeInstitutionsShares
Increased
8
750.33K
New
8
834.84K
Decreased
8
424.35K
Sold Out
5
165.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Gregory Brown
President/Chief Executive Officer/Director
David Mazzo
Vice President
William Sietsema
Independent Director
Michael Davidson
Independent Director
Cynthia Flowers
Independent Director
Steven Klosk
Independent Director
Steven Myers
Independent Director
Peter Traber
Independent Director
Anne Whitaker
No Data
No Data
About CLBS
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).

Webull offers kinds of Caladrius Biosciences Inc stock information, including NASDAQ:CLBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLBS stock methods without spending real money on the virtual paper trading platform.